| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
L-372662 targets multiple receptors. It is a potent, non-peptide antagonist of the neurokinin-1 (NK1) receptor. It is also a potent and orally active non-peptide oxytocin antagonist with a Ki value of 4.8 nM. The compound has a Kd value of 4.8. By blocking NK1 receptors, L-372662 inhibits the effects of substance P, a neuropeptide involved in pain, inflammation, and emesis. By blocking oxytocin receptors, it inhibits oxytocin-induced uterine contractions. This dual receptor antagonism makes L-372662 a unique research tool.
|
|---|---|
| ln Vitro |
In vitro, L-372662 is a potent antagonist of the NK1 receptor and the oxytocin receptor. It has a Ki value of 4.8 nM for the oxytocin receptor. The compound's activity is typically measured using receptor binding assays and functional assays. In functional assays, L-372662 inhibits agonist-induced signaling at both NK1 and oxytocin receptors. Its good oral bioavailability and blood-brain barrier penetration make it suitable for in vivo studies.
|
| ln Vivo |
In late gestation pregnant rhesus monkeys, L-372662 is an antagonist of oxytocin-induced uterine contractions (AD50 = 36 μg/kg), oral bioavailability (F = 90% in dogs), and water solubility (10 mg/ml).
In vivo, L-372662 is an antagonist of oxytocin-induced uterine contractions in late gestation pregnant rhesus monkeys with an AD50 of 36 micrograms/kg. It exhibits good oral bioavailability (F = 90% in dogs) and aqueous solubility (10 mg/mL). The compound's ability to penetrate the blood-brain barrier makes it suitable for studying central nervous system pathways. These in vivo studies confirm the compound's potent antagonistic activity at the oxytocin receptor. |
| Enzyme Assay |
In vitro receptor binding assays for L-372662 measure its affinity for the NK1 receptor and the oxytocin receptor. Membranes from cells expressing the respective receptors are incubated with radiolabeled ligands and varying concentrations of L-372662. The Ki values are determined from competition binding curves. For the oxytocin receptor, the Ki is 4.8 nM. Functional assays measure the compound's ability to inhibit agonist-induced signaling, such as calcium mobilization or inositol phosphate accumulation, in cells expressing the NK1 or oxytocin receptors.
|
| Cell Assay |
In vitro cell-based assays for L-372662 are used to study its effects on NK1 and oxytocin receptor signaling. Cells expressing the NK1 receptor or oxytocin receptor are treated with agonists (e.g., substance P or oxytocin) in the presence or absence of L-372662. The inhibition of downstream signaling, such as calcium mobilization, is measured. The IC50 is determined from dose-response curves. These assays confirm the compound's potent antagonistic activity at both receptors in a cellular context.
|
| Animal Protocol |
In vivo animal experiments for L-372662 have been conducted in pregnant rhesus monkeys to study its effects on oxytocin-induced uterine contractions. In a typical study, L-372662 is administered to late gestation pregnant rhesus monkeys, and uterine contractions are measured. The compound has an AD50 of 36 micrograms/kg for inhibiting oxytocin-induced contractions. Pharmacokinetic studies in dogs have shown that L-372662 has good oral bioavailability (F = 90%). These studies confirm the in vivo efficacy of L-372662 as an oxytocin antagonist.
|
| ADME/Pharmacokinetics |
L-372662 has a molecular weight of 586.68 g/mol and a molecular formula of C33H38N4O6. It is a solid compound. It is soluble in DMSO and other organic solvents, with aqueous solubility of 10 mg/mL. For storage, it is recommended to keep the powder at -20°C. Detailed pharmacokinetic properties have been characterized, including good oral bioavailability (F = 90% in dogs) and blood-brain barrier penetration. The compound is suitable for in vivo studies.
|
| Toxicity/Toxicokinetics |
Detailed toxicity data for L-372662 is not provided in standard product descriptions. As a research compound, its toxicity profile has not been extensively characterized. In vivo studies have used L-372662 at doses that are effective in inhibiting uterine contractions without reported overt toxicity. However, comprehensive toxicological studies have not been reported. As with all research chemicals, standard laboratory safety precautions should be followed when handling L-372662. Its use is limited to research applications and it is not intended for human or veterinary use.
|
| References |
|
| Additional Infomation |
L-372662 is a research compound and is not approved for any clinical or therapeutic use. It is a potent, non-peptide antagonist of the neurokinin-1 (NK1) receptor and a potent and orally active non-peptide oxytocin antagonist with a Ki value of 4.8 nM. It exhibits good oral bioavailability and blood-brain barrier penetration. L-372662 has been studied for its effects on oxytocin-induced uterine contractions in pregnant rhesus monkeys (AD50 = 36 micrograms/kg). The compound is a valuable research tool for studying NK1 and oxytocin receptor pharmacology.
|
| Molecular Formula |
C33H38N4O6
|
|---|---|
| Molecular Weight |
586.69
|
| Exact Mass |
586.279
|
| CAS # |
162045-26-3
|
| PubChem CID |
5311202
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
810.8±65.0 °C at 760 mmHg
|
| Flash Point |
444.2±34.3 °C
|
| Vapour Pressure |
0.0±2.9 mmHg at 25°C
|
| Index of Refraction |
1.647
|
| LogP |
2.07
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
43
|
| Complexity |
938
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
SKWSXDUHUVMPBT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C33H38N4O6/c1-23-24(7-5-15-36(23)40)21-34-16-13-27(14-17-34)43-28-9-10-29(31(20-28)41-2)32(38)35-18-11-26(12-19-35)37-30-8-4-3-6-25(30)22-42-33(37)39/h3-10,15,20,26-27H,11-14,16-19,21-22H2,1-2H3
|
| Chemical Name |
1-[1-[2-methoxy-4-[1-[(2-methyl-1-oxidopyridin-1-ium-3-yl)methyl]piperidin-4-yl]oxybenzoyl]piperidin-4-yl]-4H-3,1-benzoxazin-2-one
|
| Synonyms |
L-372662 L372662 L 372662
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~170.45 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.26 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.26 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.26 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7045 mL | 8.5224 mL | 17.0448 mL | |
| 5 mM | 0.3409 mL | 1.7045 mL | 3.4090 mL | |
| 10 mM | 0.1704 mL | 0.8522 mL | 1.7045 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
